Therefore, we performed a retrospective study to explore the therapeutic effect and safety of osimertinib plus RT and further compared the clinical outcomes of osimertinib plus RT with those of osimertinib alone in NSCLC patients with EGFR-activating mutations and BMs. Here, EGFR is linked to non-small cell lung carcinoma.